05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
07:00 , Aug 20, 2015 |  BC Innovations  |  Strategy

Starting earlier at GSK

GlaxoSmithKline plc is extending its "buy-over-build" strategy for research with a new arm of academic outsourcing targeted at even earlier stage projects than the translational and clinical alliances it already has in place. With a...
07:00 , Jul 9, 2015 |  BC Innovations  |  Strategy

GSK aims higher in genetics

GlaxoSmithKline plc 's launch of the independent Altius Institute for Biomedical Sciences last month showed the pharma is making the use of cutting-edge research and technologies for gene regulation a top priority in guiding its...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

GlaxoSmithKline, Altius Institute deal

GlaxoSmithKline signed a 10-year deal with Altius to research technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions in health and disease. GSK will provide $95 million in...